Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033

OBJECTIVE: To evaluate the safety, tolerability, and pharmacokinetics (PK) of BIIB033 (anti-LINGO-1 monoclonal antibody) in healthy volunteers and participants with multiple sclerosis (MS). METHODS: In 2 separate randomized, placebo-controlled studies, single ascending doses (SAD; 0.1–100 mg/kg) of...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Jonathan Q., Rana, Jitesh, Barkhof, Frederik, Melamed, Isaac, Gevorkyan, Hakop, Wattjes, Mike P., de Jong, Remko, Brosofsky, Kristin, Ray, Soma, Xu, Lei, Zhao, Jim, Parr, Edward, Cadavid, Diego
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202679/
https://www.ncbi.nlm.nih.gov/pubmed/25340070
http://dx.doi.org/10.1212/NXI.0000000000000018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202679/
https://www.ncbi.nlm.nih.gov/pubmed/25340070
http://dx.doi.org/10.1212/NXI.0000000000000018

Ejemplares similares